Company2018-09-22T12:58:55+00:00

About ProLung

ProLung is a medical technology company specializing in innovative predictive analytics technology and non-invasive test for the risk stratification of indeterminate pulmonary nodules that can lead to lung cancer. The rapid, non-invasive, and radiation-free ProLung Test™ was developed to rapidly assess the risk of malignancy in lung nodules found in the chest. Currently, patients typically wait between three months and three and one-half years to have the risk of malignancy assessed through periodic CT scans. Until malignancy is determined to be likely, invasive biopsy and treatment may be significantly delayed. The ProLung Test can be completed in fewer than 30 minutes and can provide results within 24 hours. 

According to the American Cancer Society and the American Lung Association, lung cancer is the leading cause of cancer death among both men and women; about one out of four cancer deaths are from lung cancer.1 They estimate that in 2017, more people in the United States will die of lung cancer than of colon, breast, and prostate cancers combined.2 Until recently, asymptomatic lung cancer was detected only incidentally.3 Currently, a lung cancer screen now reimbursed by Medicare, is performed by low-dose computed tomography.4  This may lead to a dramatic increase in the number of individuals with lung nodules detected, which is intensifying the need for a risk stratification test such as the ProLung Test.

1 American Lung Association (ALA) (full text)
2 American Cancer Society (ACS) (full text)
3 National Lung Screening Trial Research Team (NLST). Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011; 365:395-409 (full text)
4 Centers for Medicare & Medicaid Services (full text)

Our mission is to make a difference in time by striving to improve outcomes for potential lung cancer patients through early predictive technologies; provide cost savings to patients, payers, and providers; and to provide a fair return on investment to shareholders and other stakeholders.

ProLung is committed to making a positive and significant impact on the healthcare community and to being socially responsible in all its endeavors.

The Company has adopted the Code of Ethics for Senior Executives, Financial Officers, Members of the Management Executive Committee, and Directors, which constitutes a code of ethics that applies to the principal executive officer, principal financial officer, principal accounting officer, or controller, or persons performing similar functions, as defined in Item 406 of Regulation S-K under the Exchange Act.

Meet Our Team

Jared Bauer
 Interim CEO

Mr. Bauer was appointed interim CEO in September 2018. He is also the Chief Executive Officer of ApolloDx, LLC, an in vitro mobile point-of-care diagnostic company, and the Chief Executive Officer of CibusDx Inc., a company delivering technology that improves food safety testing. In 2012, Mr. Bauer previously founded Exuro Medical and acquired BurnFree Products. In just two years with a focus on sustainable revenue generation, he led the Exuro Medical team to expand BurnFree distribution to 58 countries, managing regulatory processes, re-working quality systems and making BurnFree the second largest burn treatment product line in the world. Mr. Bauer exited Exuro Medical with a 33x return in 2016. Mr. Bauer also co-founded and led the Idaho Business Council, which is a non-partisan collaboration between the state’s business community and its research universities to promote Idaho-based research and economic development. Mr. Bauer currently serves as a trustee at The Oliver Fund, which is a non-profit he co-founded, and recently served as an adjunct professor of entrepreneurship at the LDS Business College.

Michael A. Garff
Chief Operating Officer & Director

Mr. Garff joined ProLung as the Chief Operating Officer in June 2009. At ProLung, he obtained European regulatory approval (CE Mark), organized and operates manufacturing, acquired clinical sites at premier cancer hospitals, and designed and implemented a certified ISO 13485 quality management system. Currently, he oversees ProLung’s product development, manufacturing, clinical studies, regulatory affairs, FDA submissions, quality audits, data analysis, and patents. Prior to ProLung, he was involved with the Pierre Lassonde Entrepreneur Center where he served as a Director. While there he helped launch several biomedical companies. Previously, Mr. Garff also earned a reputation as an organization builder and effective project manager at the Biomedical Informatics Department of the University of Utah and US Bank. His commercialization experience and entrepreneurial attitude towards challenges gives him uncommon perspective in developing technology into products and creating successful companies. He holds a BS in Business Finance and an MBA from the University of Utah.

Rex Chin-Wei Yung, MD, FCCP
Chief Scientific Officer

Dr. Yung is the Chief Scientific Officer and is leading the evaluation of opportunities to expand our underlying science and indications through his expertise in translational research of lung cancer biomarkers and early cancer detection through imaging and bronchoscopy. Previously, Dr. Yung was the Director of Pulmonary Oncology and Director of Bronchoscopy at Johns Hopkins University School of Medicine (JHU). Dr. Yung remains an adjunct faculty in the Department of Oncology at JHU. Dr. Yung is a fellow of the American College of Chest Physicians. He is board certified in Internal Medicine, Pulmonary and Critical Care Medicine and has served on the executive and editorial boards of the American Association of Bronchology and Interventional Pulmonology and Journal of Bronchology and Interventional Pulmonology. Dr. Yung graduated from Harvard University and received his MD from the University of California at Los Angeles (UCLA).

Jeffrey S. O’Driscoll, MD, FACEP
Chief Medical Officer

Dr. O’Driscoll is the Chief Medical Officer and has treated patients in the emergency department for over 25 years. He has practiced at a level-1 trauma center and teaching hospital, where he served as the chair of emergency medicine for eight years. Doctor O’Driscoll is board certified in internal medicine and is a fellow of the American College of Emergency Physicians. He served as medical director and consultant to Intermountain Healthcare’s Emergency Department Development Team and Emergency Physician Information Systems Advisory Group. He previously chaired a regional pharmacy and therapeutics committee for Intermountain Healthcare and served on their corporate pharmacy and therapeutics committee. Dr. O’Driscoll is presently on a leave of absence from the emergency department while working with ProLung.

Andy C. Robertson
Vice President of Business Development

Mr. Robertson joined ProLung in July 2017 and is focused on identifying mutually beneficial strategic partnerships, establishing and strengthening relationships with sales distribution partners, gaining reimbursement and utilizing ProLung’s CE mark. Over the course of more than 20 years in the global medical device or medtech industry, he has held upstream and downstream marketing positions of increasing responsibility, been publicly recognized with marketing awards and launched 15 medical devices. He brings an invaluable professional perspective and organizational savvy from his tenure with smaller medical device manufacturers (Utah Medical Products and Megadyne now J&J Ethicon) to some of the largest (Covidien now Medtronic, Becton Dickinson and CR Bard). He holds a Bachelor of Science in Marketing from the University of Utah. In particular, Mr. Robertson has a proven track record of profitably delivering what health care providers and patients want.

Kristin M. Larson, NP
Director of Clinical Affairs

Ms. Larson is the Director of Clinical Affairs. She has been instrumental in conducting our pivotal clinical validation study (PL-208), as well as leading our worldwide training and education. Ms. Larson has strong professional relationships with institutions, physician investigators, and study staff around the world. Prior to joining ProLung in 2015, she held educator positions for pharmaceutical and medical device companies. Ms. Larson is currently an adjunct instructor for the University of North Dakota Nurse Practitioner Program and has patient care experience encompassing critical care, occupational medicine and chronic kidney disease. She has numerous scientific publications and clinical awards to her credit. Ms. Larson has an undergraduate degree from the University of North Dakota and Masters Degree in Nursing from the Medical University of South Carolina.

Board of Directors

Robert Raybould, Member of ProLung Board of Directors

Robert W. Raybould
Vice Chair of the Board, Director

Mr. Raybould serves as a Director of ProLung. He began his career serving in the U.S. Army and then with Eastman Kodak in Rochester, New York. He then co-founded Realvest, a real estate investment company. Mr. Raybould has helped found several financial companies including TRI Capital Corporation, DTM Research, and Greenhill Financial, which became Arlington Value Capital, LLC. Mr. Raybould holds a BS in Banking and Finance as well as an MBA from the University of Utah.

Jared Bauer, newest addition to the ProLung Board of Directors

Jared Bauer

Director and Interim CEO

Mr. Bauer was appointed interim CEO in September 2018. He is also the Chief Executive Officer of ApolloDx, LLC, an in vitro mobile point-of-care diagnostic company, and the Chief Executive Officer of CibusDx Inc., a company delivering technology that improves food safety testing. In 2012, Mr. Bauer previously founded Exuro Medical and acquired BurnFree Products. In just two years with a focus on sustainable revenue generation, he led the Exuro Medical team to expand BurnFree distribution to 58 countries, managing regulatory processes, re-working quality systems and making BurnFree the second largest burn treatment product line in the world. Mr. Bauer exited Exuro Medical with a 33x return in 2016. Mr. Bauer also co-founded and led the Idaho Business Council, which is a non-partisan collaboration between the state’s business community and its research universities to promote Idaho-based research and economic development. Mr. Bauer currently serves as a trustee at The Oliver Fund, which is a non-profit he co-founded, and recently served as an adjunct professor of entrepreneurship at the LDS Business College.

J. Scott Nixon, CPA
Director

J. Scott Nixon, CPA retired in 2015 as a partner with PricewaterhouseCoopers (PwC) where he spent over 31 years in various roles including Office Managing Partner and engagement partner over public and private companies in many industries. His career involved providing audit and business advisory services, was involved in numerous complex filings with the SEC, and was instrumental in resolving unique accounting issues with the SEC on behalf of his clients. In 2007, Scott returned from a four-year assignment in São Paulo, Brazil where he represented various interests of the PwC global firm to the 18 member firms in South and Central America, and led the implementation and compliance of the Sarbanes-Oxley requirements in those countries. Scott serves on several boards of directors and is a National Association of Corporate Directors (NACD) Board Leadership Fellow. He holds both a BA and Master of Accounting from Utah State University.

Michael Garff, member of ProLung Board of Drectors

Michael A. Garff
Interim Chief Operating Officer, Director

Mr. Garff joined ProLung as the Chief Operating Officer in June 2009. At ProLung, he obtained European regulatory approval (CE Mark), organized and operates manufacturing, acquired clinical sites at premier cancer hospitals, and designed and implemented a certified ISO 13485 quality management system. Currently, he oversees ProLung’s product development, manufacturing, clinical studies, regulatory affairs, FDA submissions, quality audits, data analysis, and patents. Prior to ProLung, he was involved with the Pierre Lassonde Entrepreneur Center where he served as a Director. While there he helped launch several biomedical companies. Previously, Mr. Garff also earned a reputation as an organization builder and effective project manager at the Biomedical Informatics Department of the University of Utah and US Bank. His commercialization experience and entrepreneurial attitude towards challenges gives him uncommon perspective in developing technology into products and creating successful companies. He holds a BS in Business Finance and an MBA from the University of Utah.

Mark Anderson, member of ProLung Board of Directors

Mark V. Anderson, CPA
 Director

Mr. Anderson, a Certified Public Accountant (CPA), is a Partner at Haynie & Company. He was the ProLung Chief Financial Officer from 2017 through 2018. Prior to joining our team in mid-2017, Mr. Anderson was a partner with Eide Bailly LLP and previous to that a partner at Hansen, Barnett and Maxwell. During Mr. Anderson’s more than 20 years in public accounting, his roles included Quality Control Director and Engagement Partner for public and private companies in numerous industries. Mr. Anderson’s experience with complex Securities and Exchange Commission (SEC) filings on behalf of his clients is a tremendous asset for ProLung, which is a publicly reporting company. Mr. Anderson holds both a Bachelor of Science and Masters of Professional Accountancy degree from Weber State University.